Consolidated Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 3,409,310	$ 1,126,124
Short-term investments	357,391	452,301
Accounts receivable	246,552	378,865
Other current assets	56,751	45,381
Total current assets	4,070,004	2,002,671
Equipment, net	9,233	15,514
Other long-term assets		18,667
Total assets	4,079,237	2,036,852
Current liabilities:
Accounts payable	301,618	263,573
Accrued expenses	210,223	782,579
Accrued warrant liability	275,494	6,414
Total current liabilities	787,335	1,052,566
Non-current liabilities
Total liabilities	787,335	1,052,566
Stockholders’ equity:
Preferred stock, $.005 par value; 1,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 0 shares issued and outstanding as of June 30, 2020 and December 31, 2019
Common stock, $.005 par value; 25,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 12,927,988 and 11,298,239 shares issued and outstanding as of June 30, 2020 and December 31, 2019	64,163	56,487
Additional paid-in capital	166,503,441	163,161,523
Accumulated other comprehensive loss	(612,124)	(568,030)
Accumulated deficit	(167,663,942)	(166,705,572)
Total Cleveland BioLabs, Inc. stockholders’ deficit	(1,708,462)	(4,055,592)
Noncontrolling interest in stockholders’ equity	5,000,364	5,039,878
Total stockholders’ equity	3,291,902	984,286
Total liabilities and stockholders’ equity	$ 4,079,237	$ 2,036,852